Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.71 |
| ▸ | CA9 | Q16790 | 5/20 | 0.71 |
| ▸ | CA1 | P00915 | 3/20 | 0.71 |
| ▸ | CA2 | P00918 | 2/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | LCK | P06239 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.54 |
| ▸ | GLA | P06280 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | IL2 | P60568 | 2/20 | 0.52 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.52 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.52 |
| ▸ | ALDH1B1 | P30837 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3361018 | 0.89 | CA12 (0.70) | CA12CA9CA1CA2KDM4E | |
| SCHEMBL382083 | 0.88 | CA12 (0.74) | CA12CA9CA1CA2KDM4E | |
| SCHEMBL6228083 | 0.88 | CA12 (0.74) | CA12CA9CA1CA2KDM4E | |
| SCHEMBL578576 | 0.87 | CA12 (0.64) | CA12CA9CA1CA2KDM4E | |
| SCHEMBL724524 | 0.85 | CA12 (0.61) | CA12CA9CA1CA2KDM4E | |
| SCHEMBL724528 | 0.85 | CA12 (0.61) | CA12CA9CA1CA2KDM4E | |
| SCHEMBL8098515 | 0.84 | CA12 (0.62) | CA12CA9CA1CA2KDM4E | |
| SCHEMBL8097205 | 0.83 | CA12 (0.67) | CA12CA9CA1CA2KDM4E | |
| SCHEMBL152641 | 0.83 | CA12 (1.00) | CA12CA9CA1CA2KDM4E | |
| SCHEMBL10048269 | 0.83 | CA12 (1.00) | CA12CA9CA1CA2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
| EP-1062361-A2 | WATER-SOLUBLE COUMARIN FLUORESCENT ENZYME SUBSTRATES | ABBOTT LABORATORIES (US) | 2000-12-27 | — | — | EP | disclosed |
| US-5998593-A | COUMARIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1999-12-07 | — | — | US | disclosed |
| WO-1999046402-A2 | WATER-SOLUBLE COUMARIN FLUORESCENT ENZYME SUBSTRATES | ABBOTT LABORATORIES (US) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | CA12 4856/4885CA9 4872/4885CA1 4868/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | CA12 1810/4885CA9 1667/4885CA1 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.